ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
chronicchronic-kidney-diseasekidney-diseaseskidney-failurerenal-insufficiencysecondaryvitamin-dvitamin-d-deficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders#250355
- Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism#1087671
- the Study on Prognostic for Hemodialysis Patients#896631
- Chapter 12: Preparation for parathyroid surgery#161297
- Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism#1093785
Record · ID 911377
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive